BioSig Technologies Inc has announced the appointment of Access Strategy Partners, Inc (ASPI) to advise the company on the next phase of its commercial roll-out.
BioSig said the healthcare management firm is expected to enhance the company’s market access strategy as BioSig expands the installation base of its signal processing technology for arrhythmia care.
“Look closely at ASPI’s track record in helping emerging medical device companies, and you will see what we saw – strong revenue growth rates with sustainability,” BioSig Technologies CEO Kenneth Londoner said in a statement.
READ: BioSig Technologies expands its clinical footprint in Florida, installs PURE EP System in HCA Healthcare-operated hospital
“We look forward to learning from some of the brightest minds in medical device sales as we leverage the key insights from our initial commercial efforts to bring our disruptive technology to the next level of hospitals nationwide,” Londoner added.
Under the terms of the new collaboration, ASPI will advise BioSig on all aspects of commercial strategy, including economic value modeling, hospital administration engagement, and contracting.
The company noted that Boston-based ASPI provides “deep” expertise in commercialization, contract management, execution, and value proposition optimization.
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
The company’s PURE EP is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Contact Sean at sean@proactiveinvestors.com